All In Biotech

Drug Trial Radar · NCT05106335

A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC

A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Who Progressed on Prior Immune Checkpoint Inhibitor Treatment and Platinum-Based Chemotherapy

Last checked: Nov 20, 2026Latest source record: Aug 16, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1

Actual

Start

Jan 6, 2022

Primary completion

May 11, 2022

Study completion May 11, 2022

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.

Conditions

  • Advanced NSCLC

Interventions

  • camrelizumab + famitinibDrug

    camrelizumab for intravenous injection; famitinib malate capsules for oral administration

  • famitinibDrug

    famitinib malate capsules for oral administration

  • docetaxelDrug

    docetaxel for intravenous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. OSTime frame: up to 4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Subei People's Hospital of Jiangsu Province

    Yangzhou, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.